phenylephrine hydrochloride; promethazine hydrochloride
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
PHENERGAN VC is an oral syrup combining phenylephrine hydrochloride (a decongestant) and promethazine hydrochloride (an antihistamine/anticholinergic agent). It is indicated for symptomatic relief of upper respiratory congestion, cough, and allergy-related symptoms. The formulation addresses both nasal congestion through alpha-adrenergic stimulation and allergic/histaminergic responses through H1 antagonism.
As a mature legacy product approaching loss of exclusivity with moderate competitive pressure (30), brand team size and commercial investment are likely modest and focused on defensive positioning rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job postings reflect the product's mature, legacy status with minimal hiring. Roles on PHENERGAN VC are typically defensive, focused on market retention, compliance, and operational efficiency rather than growth or innovation.
Worked on PHENERGAN VC at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo